The recently formed scientific advisory board of Europital anticipates that a deficit in the clinical knowledge of smaller biotechs may lead to slow development in 2021.
The recently formed scientific advisory board (SAB) of contract research organization, Europital, anticipates that a deficit in the clinical knowledge of smaller biotechs may lead to slow biotech development in 2021.
According to a Feb. 8, 2021 press release, the SAB, which comprises a group of clinical key-opinion leaders and specialized industry experts, forewarns of a slowing of trials in 2021 due to the clinical knowledge deficit. Additionally, the board believes that investment communities will start to take a holistic look at biotechs and partners to ensure there is deep therapeutic expertise available.
“The drug discovery pipeline is increasingly made up of smaller and more nimble innovators with limited clinical experience in-house. Yet, with many of the low hanging fruit already having been developed, molecules and biologies are becoming ever more complex,” said Dr. Mohamed El Malt, chief medical officer of Europital, in the press release. “The challenge for small and medium pharma and biotechs is how to access appropriate high-quality clinical knowledge—and this clinical deficit over the next few years is set to be a critical factor in any candidates advancement.
“It’s no secret that unlike the larger pharma companies that can pull in the best resources from the largest CROs, smaller companies must increasingly compete to ensure they can access the best clinical knowledge, as this can be the difference between delays due poor trial management and planning, and even, a project’s potential success or failure,” added El Malt.
Source: Europital
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.